Biopharma & Life Sciences
Vanda Pharmaceuticals Executive Compensation (FY25)
VNDA · Executive and director compensation, fiscal 2025 only
Data as of September 7, 2026Latest filing (8-K): June 5, 2026
147 figures on this page: 145 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
Total compensation for Mihael Polymeropoulos, President, Chief Executive Officer and Chairman of the Board, came to $3,851,468 in fiscal 2025, and shareholders supported the say-on-pay proposal with 91.8% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025. The disclosed peer group includes ACADIA Pharmaceuticals, Agios Pharmaceuticals, Amarin Corporation, Amicus Therapeutics and Corcept Therapeutics, among others. The 2026 Compensation Peer Group names Akebia Therapeutics, Arcturus Therapeutics Holdings, Axsome Therapeutics, Heron Therapeutics and Rigel Pharmaceuticals. For fiscal 2025, the company reported 5 named executive officers.
Frequently asked questions
Answers drawn from the data on this page.
Who is Vanda Pharmaceuticals' chief executive and what were they paid?
Total compensation for Mihael Polymeropoulos, President, Chief Executive Officer and Chairman of the Board, came to $3,851,468 in fiscal 2025.
What was Vanda Pharmaceuticals' say-on-pay result?
Shareholders supported the say-on-pay proposal with 91.8% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.
Which companies are in Vanda Pharmaceuticals' peer group?
The disclosed peer group includes ACADIA Pharmaceuticals, Agios Pharmaceuticals, Amarin Corporation, Amicus Therapeutics and Corcept Therapeutics, among others. The 2026 Compensation Peer Group names Akebia Therapeutics, Arcturus Therapeutics Holdings, Axsome Therapeutics, Heron Therapeutics and Rigel Pharmaceuticals.
What is Vanda Pharmaceuticals' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 23.1:1, against median employee compensation of $166,623.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Mihael Polymeropoulos President, Chief Executive Officer and Chairman of the Board | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Joakim Wijkstrom Senior Vice President, Chief Marketing Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Timothy Williams Senior Vice President, General Counsel and Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Gunther Birznieks Senior Vice President, Business Development | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Gunther Birznieks | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Joakim Wijkstrom | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Kevin Moran | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Mihael H. Polymeropoulos | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Timothy Williams | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Mihael Polymeropoulos | Option | ◇ | — | ◇ | 2/27/2032 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/15/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Joakim Wijkstrom | Option | ◇ | — | ◇ | 2/15/2033 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/27/2032 | |
| Gunther Birznieks | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/27/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/15/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Timothy Williams | Option | ◇ | — | ◇ | 2/27/2032 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/15/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Kevin Moran | Option | ◇ | — | ◇ | 2/15/2033 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/27/2032 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Richard W. Dugan Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
Anne Sempowski Ward | ◇ | ◇ | — | — | — | — | ◇ |
Phaedra S. Chrousos | ◇ | ◇ | — | — | — | — | ◇ |
Tage Honoré | ◇ | ◇ | — | — | — | — | ◇ |
Stephen Ray Mitchell | ◇ | ◇ | — | — | — | — | ◇ |
Mihael H. Polymeropoulos and Charles C. Duncan served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- ACADIA Pharmaceuticals ACAD
- Agios Pharmaceuticals AGIO
- Amarin Corporation AMRN
- Amicus Therapeutics FOLD
- Corcept Therapeutics CORT
- Enanta Pharmaceuticals ENTA
- Intra-Cellular Therapies ITCI
- Ironwood Pharmaceuticals IRWD
- Lexicon Pharmaceuticals LXRX
- Omeros Corporation OMER
- Pacira BioSciences PCRX
- Sage Therapeutics SAGE
- Supernus Pharmaceuticals SUPN
- Travere Therapeutics TVTX
2026 Compensation Peer Group
- Akebia Therapeutics AKBA
- Arcturus Therapeutics Holdings ARCT
- Axsome Therapeutics AXSM
- Heron Therapeutics HRTX
- Rigel Pharmaceuticals RIGL
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 4, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 5, 2025 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Vanda Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Vanda Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
147 figures on this page: 145 cited to the filing that reported them, 2 calculated from figures it prints.
145 cited to the filing
2 calculated from the filing
Documents cited
- 0001628280-26-041298Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-26-0268932025 Director Compensation · 2025 Summary Compensation Table · Compensation of Directors · Grants of Plan-Based Awards · and 1 more section
- 0001628280-25-029678Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Vanda Pharmaceuticals executive compensation, FY2025.” https://intel.velarion.ai/comp/VNDA (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Vanda Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Vanda Pharmaceuticals discloses
The companies named in VNDA's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}